Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Receivables (2019 - 2025)

Seres Therapeutics (MCRB) has disclosed Receivables for 5 consecutive years, with $157000.0 as the latest value for Q4 2025.

  • Quarterly Receivables fell 97.55% to $157000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $157000.0 through Dec 2025, down 97.55% year-over-year, with the annual reading at $157000.0 for FY2025, 97.55% down from the prior year.
  • Receivables hit $157000.0 in Q4 2025 for Seres Therapeutics, down from $404000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $9.0 million in Q1 2025 to a low of $157000.0 in Q4 2025.
  • Historically, Receivables has averaged $3.0 million across 3 years, with a median of $1.3 million in 2021.
  • Biggest five-year swings in Receivables: rose 24.95% in 2021 and later plummeted 97.55% in 2025.
  • Year by year, Receivables stood at $1.2 million in 2021, then skyrocketed by 412.56% to $6.4 million in 2024, then tumbled by 97.55% to $157000.0 in 2025.
  • Business Quant data shows Receivables for MCRB at $157000.0 in Q4 2025, $404000.0 in Q3 2025, and $9.0 million in Q1 2025.